Estradiol Valerate in COC Has More Favorable Inflammatory Profile Than Synthetic Ethinyl Estradiol: A Randomized Trial

• Published in: The journal of clinical endocrinology and metabolism 2020-07, Vol.105 (7), p.e2483-e2490
• Main Authors: Kangasniemi, Marika H, Haverinen, Annina, Luiro, Kaisu, Hiltunen, J Kalervo, Komsi, Elina K, Arffman, Riikka K, Heikinheimo, Oskari, Tapanainen, Juha S, Piltonen, Terhi T
• Format: Article
• Language: English
• Subjects: Adult; C-Reactive Protein - metabolism; Cholesterol - blood; Contraceptives, Oral, Combined - administration & dosage; Estradiol - administration & dosage; Ethinyl Estradiol - administration & dosage; Female; Humans; Inflammation - metabolism; Lipid Metabolism - drug effects; Lipoproteins, LDL - blood; Nandrolone - administration & dosage; Nandrolone - analogs & derivatives; Serum Amyloid P-Component - metabolism; Triglycerides - blood; Young Adult
• ISSN: 0021-972X; 1945-7197
• DOI: 10.1210/clinem/dgaa186

Combined oral contraceptives (COCs) alter inflammatory status and lipid metabolism. Whether different estrogens have different effects is poorly understood. We compared the effects of COCs containing ethinyl estradiol (EE) or estradiol valerate (EV) and dienogest (DNG) with those containing DNG only on inflammation and lipid metabolism. Randomized, controlled, open-label clinical trial. Two-center study in Helsinki and Oulu University Hospitals. Fifty-nine healthy, young, nonsmoking women with regular menstrual cycles. Age, body mass index, and waist-to-hip ratio were comparable in all study groups at the beginning. Fifty-six women completed the study (EV + DNG, n = 20; EE + DNG, n = 19; DNG only, n = 17). Nine-week continuous use of COCs containing either EV + DNG or EE + DNG, or DNG only as control. Parameters of chronic inflammation (high-sensitivity C-reactive protein [hs-CRP], and pentraxin 3 [PTX-3]) and lipid profile (high-density lipoprotein [HDL], low-density lipoprotein [LDL], triglycerides, and total cholesterol). Serum hs-CRP increased after 9-week use of EE + DNG (mean change ± standard deviation 1.10 ± 2.11 mg/L) compared with EV + DNG (-0.06 ± 0.97 mg/L, P = 0.001) or DNG only (0.13 ± 0.68 mg/L, P = 0.021). Also, PTX-3 increased in the EE + DNG group compared with EV + DNG and DNG-only groups (P = 0.017 and P = 0.003, respectively). In the EE + DNG group, HDL and triglycerides increased compared with other groups (HDL: EE + DNG 0.20 ± 0.24 mmol/L vs EV + DNG 0.02 ± 0.20 mmol/L [P = 0.002] vs DNG 0.02 ± 0.18 mmol/L [P = 0.002]; triglycerides: EE + DNG 0.45 ± 0.21 mmol/L vs EV + DNG 0.18 ± 0.36 mmol/L [P = 0.003] vs DNG 0.06 ± 0.18 mmol/L [P < 0.001]). EV + DNG and DNG only had a neutral effect on inflammation and lipids, while EE + DNG increased both hs-CRP and PTX-3 levels as well as triglycerides and HDL. ClinicalTrials.gov NCT02352090.